Automate Your Wheel Strategy on ALVO
With Tiblio's Option Bot, you can configure your own wheel strategy including ALVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALVO
- Rev/Share 1.9916
- Book/Share -0.6163
- PB -7.5286
- Debt/Equity -7.3157
- CurrentRatio 1.8211
- ROIC 0.0883
- MktCap 1445829355.0
- FreeCF/Share -0.4972
- PFCF -10.3404
- PE 20.5958
- Debt/Assets 0.9104
- DivYield 0
- ROE -0.2057
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ALVO | Deutsche Bank | Buy | Hold | -- | $8 | Nov. 4, 2025 |
| Upgrade | ALVO | Morgan Stanley | Equal Weight | Overweight | -- | $14 | Oct. 14, 2025 |
| Upgrade | ALVO | Deutsche Bank | Hold | Buy | -- | $14 | Sept. 23, 2025 |
| Initiation | ALVO | UBS | -- | Buy | -- | $18 | Feb. 14, 2025 |
News
Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation – ALVO
Published: December 04, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public. So What: If you purchased Alvotech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rose.
Read More
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
Published: November 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over the propriety of its disclosures regarding its lead drug candidate and its manufacturing operations, following a dramatic revision to the company's full-year financial forecasts.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alvotech - ALVO
Published: November 20, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alvotech ("Alvotech" or the "Company") (NASDAQ: ALVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
Published: November 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over the propriety of its disclosures regarding its lead drug candidate and its manufacturing operations, following a dramatic revision to the company's full-year financial forecasts. The firm urges investors in Alvotech who suffered significant losses to submit your losses now.
Read More
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
Published: November 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over the propriety of its disclosures regarding its lead drug candidate and its manufacturing operations, following a dramatic revision to the company's full-year financial forecasts.
Read More
Alvotech (ALVO) Q3 2025 Earnings Call Transcript
Published: November 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Alvotech ( ALVO ) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Benedikt Stefansson - VP of Investor Relations and Global Communications Robert Wessman - CEO, Founder & Executive Chairman Joseph McClellan - Chief Scientific & Technical Officer Linda Jonsdottir - Chief Financial Officer Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Thibault Boutherin - Morgan Stanley, Research Division Arvid Necander - DNB Carnegie, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Alvotech Q3 2025 Earnings Conference Call.
Read More
ALVO ALERT: Levi & Korsinsky Investigates Alvotech for Possible Securities Fraud Violations
Published: November 13, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 13, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Alvotech ("Alvotech") (NASDAQ: ALVO) concerning possible violations of federal securities laws. On November 2, 2025, Alvotech published a press release notifying investors that the Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA) for ATV05.
Read More
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
Published: November 13, 2025 by: PRNewsWire
Sentiment: Neutral
ALVO Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , Nov. 13, 2025 /PRNewswire/ -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over the propriety of its disclosures regarding its lead drug candidate and its manufacturing operations, following a dramatic revision to the company's full-year financial forecasts. The firm urges investors in Alvotech who suffered significant losses to submit your losses now.
Read More
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
Published: November 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over the propriety of its disclosures regarding its lead drug candidate and its manufacturing operations, following a dramatic revision to the company's full-year financial forecasts.
Read More
ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm
Published: November 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alvotech (ALVO) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in AlvoTech and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Read More
ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm
Published: November 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alvotech (ALVO) To Contact Him Directly To Discuss Their Options If you purchased or acquired Alvotech stock and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Read More
Analysts Estimate Alvotech (ALVO) to Report a Decline in Earnings: What to Look Out for
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Alvotech (ALVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Alvotech Shares Plunge 33% After FDA Flags Issues
Published: November 03, 2025 by: Benzinga
Sentiment: Negative
Alvotech (NASDAQ:ALVO) stock is trading lower on Monday, with a session volume of 2.32 million compared to the average volume of 395.34 thousand as per data from Benzinga Pro.
Read More
Wall Street Analysts See a 105.88% Upside in Alvotech (ALVO): Can the Stock Really Move This High?
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Alvotech (ALVO) points to a 105.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
Here's How Alvotech is Expanding its Portfolio Beyond Immunology
Published: September 30, 2025 by: Zacks Investment Research
Sentiment: Positive
ALVO accelerates growth with soaring revenues and new biosimilars in ophthalmology, oncology and neurology via global alliances.
Read More
Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
ALVO's partnership-driven model fuels surging biosimilar revenues, while TEVA leans on scale but faces debt and competitive pressures.
Read More
Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Alvotech's partnership-led strategy drives soaring biosimilar revenues, fresh approvals and a diversified pipeline across key therapies.
Read More
Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Alvotech (NASDAQ:ALVO ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants Balaji Prasad - Chief Strategy Officer Conference Call Participants Thibault Boutherin - Morgan Stanley, Research Division Presentation Thibault Boutherin Equity Analyst Okay. Perfect. So we'll start.
Read More
ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Alvotech trades near a 52-week low after a 38% drop in 2025, but soaring revenues and new biosimilar approvals highlight its growth path.
Read More
Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
Published: September 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
REYKJAVIK, Iceland, June 4, 2025 - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference, which will be held in New York, NY, September 8-10, 2025. Alvotech will be meeting with investors on Tuesday, September 9, 2025, and Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on Wednesday September 10, 2025, at 10:45 am EDT (14:45 GMT / 16:45 CET).
Read More
Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
Published: September 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
REYKJAVIK, Iceland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference, which will be held in New York, NY, September 8-10, 2025. Alvotech will be meeting with investors on Tuesday, September 9, 2025, and Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on Wednesday September 10, 2025, at 10:45 am EDT (14:45 GMT / 16:45 CET).
Read More
Wall Street Analysts Think Alvotech (ALVO) Could Surge 102.31%: Read This Before Placing a Bet
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 102.3% in Alvotech (ALVO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
ALVO preps for Q2 results as investors eye early U.S. traction for Simlandi and Selarsdi, plus pipeline progress.
Read More
Wall Street Analysts See a 91.05% Upside in Alvotech (ALVO): Can the Stock Really Move This High?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 91.1% in Alvotech (ALVO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers
Published: July 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Luxembourg (July 3, 2025) – Alvotech S.A. announces that on June 25, 2025, the proportion of own shares held by Alvotech S.A. reached 6.73%, crossing above the 5% threshold of the total number of voting rights. The above percentage has been calculated on the basis of 22,484,087 own shares out of 334,038,147 shares in issue to which voting rights are attached.
Read More
European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing …
Read More
European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for …
Read More
Wall Street Analysts Think Alvotech (ALVO) Could Surge 72.61%: Read This Before Placing a Bet
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 72.6% in Alvotech (ALVO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Goldman Sachs 46th Global Healthcare Conference, which will be held in Miami, Florida June 9-11, 2025. Members of the management team will host one-on-one meetings at the conference. Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on Wednesday June 11, 2025, at 8:00 am EDT (12:00 GMT / 14:00 CEST).
Read More
About Alvotech (ALVO)
- IPO Date 2022-06-16
- Website https://www.alvotech.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Vilhelm Robert Wessman
- Employees 1012